Natureza carries out groundbreaking development of novel anti-infective agents. We have developed two agents that fulfil unmet healthcare needs for treatments against organisms with a high level of resistance to treatment agents. Together these represent a transformative breakthrough in the search for treatments against the growing worldwide threat of AMR.
We will be taking this exciting new data to the 2023 Johnson & Johnson and BARDA BLUE KNIGHT ™ Symposium in Boston presenting data on two of our novel anti-infectives.
June 4, 2023 in Boston. Natureza have tested their antimicrobials against two of the biggest emerging threats to medicine, Candida auris and Pseudomonas, and shown that their products kill both of these organisms with no resistance seen by either. Natureza have developed new formulations so that the antimicrobials canm be inhaled into the lungs, used on the skin or encapsulated for the intestine meaning that we can treat a wider range of infections than ever before.
Natureza Develops a Patented Transformative New Class of Antibotic Agents that Overcome Bacterial Resistance. This work identifies a transformative new class of antibiotics with the novel property of lack of bacterial resistance. [read more]
Natureza’s research offers a true paradigm shift, one that would remove the imbalance in development cost by eliminating the ability of bacteria to become resistant. With the promise of new drugs being able to be marketed for years providing not only the time to recover investment, but a profit as well, a new investment environment would emerge that would encourage the development of new, much needed antibiotics. [read more]
The WHO has recognised a number of antibiotic-resistant pathogens as posing the greatest threat to human health. It further concluded that mortality and morbidity from resistant infections is on the rise globally, the clinical anti-bacterial pipeline remains insufficient, and the pipeline outlook remains bleak (WHO 2019). [read more]